rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    TSHA
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Taysha Gene Therapies Q3 Earnings Call Highlights
      Nov 12Yahoo FinanceTSHA
      Taysha Gene Therapies Q3 2026 Earnings Call Transcript
      Nov 12BenzingaTSHA
      Taysha Gene Therapies Reports Third Quarter 2026 Financial Results and Provides Corporate Update
      Nov 12Yahoo FinanceTSHA
      Taysha Gene Therapies earnings up next as analysts eye Rett trial
      Nov 11Investing.comTSHA
      Earnings To Watch: Taysha Gene Therapies Inc (TSHA) Q3 2026 -- GF Value Sees 24% Downside
      Nov 11Yahoo FinanceTSHA
      Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      DALLAS, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on November 2, 2026, the Compensation Committee of Taysha's Board of Directors granted two new employees, in the aggregate, restricted stock units (RSUs) representing 25,000 shares of the Com

      Nov 6Yahoo FinanceTSHA
      Taysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12
      Nov 5Yahoo FinanceTSHA
      Taysha Gene Therapies (TSHA) Stock Looks Rich Against Book Value
      Oct 30Yahoo FinanceTSHA
      Does Early Rett Trial Success Change The Bull Case For Taysha Gene Therapies (TSHA)?
      Oct 19Yahoo FinanceTSHA
      Taysha Gene Therapies stock hits 52-week low at 3.69 USD
      Oct 13Investing.comTSHA
      Taysha Gene Therapies (TSHA) Stock May Be Above Fair Value On Book Value
      Oct 9Yahoo FinanceTSHA
      Taysha Gene Therapies (TSHA) Faces A Split Valuation Debate, Is It Really 66% Below Fair Value?
      Oct 9Yahoo FinanceTSHA
      Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting

      DALLAS, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced multiple encore presentations supporting its TSHA-102 program in clinical evaluation for Rett syndrome at the 55th Child Neurology Society Annual Meeting, taking place in Montréal, Québec, Canada,

      Oct 1Yahoo FinanceTSHA
      Wolfe Research Initiates Taysha Gene Therapies at Outperform

      Taysha Gene Therapies (TSHA) has an average rating of buy and mean price target of $13, according to

      Sep 17Yahoo FinanceTSHA
      Taysha Gene Therapies: A Bull Case That Does Not Require The Fastest Approval
      Sep 11Seeking AlphaNGNETSHA
      Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      DALLAS, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on September 1, 2026, the Compensation Committee of Taysha's Board of Directors granted five new employees restricted stock units (RSUs) representing 314,000 shares of the Company’s common s

      Sep 4Yahoo FinanceTSHA

      This is the newest page. Registered accounts read further back.